Advertisement

Updated November 26th, 2021 at 19:51 IST

'Miracle' COVID booster would immunise kids lifelong: Dr Ella at Republic Economic Summit

Bharat Biotech MD, Dr. Krishna Ella explained the logic behind booster shot and called it a "miracle dose" that can provide lifetime immunity in children.

Reported by: Harsh Vardhan
republic Economic Summit
Image: AP/ANI | Image:self
Advertisement

Speaking at the Republic Economic Summit on Friday, November 26, MD of Covaxin-producing Bharat Biotech, Dr Krishna Ella explained the logic behind administering a booster shot. Calling the booster shot a "miracle dose", Dr Ella stated that a third dose of Covaxin will give lifetime immunity to the recipient. Using children as an example for his explanation, he said,

A child is given three-dose vaccine. The first dose, zero (month), second dose, one month, third dose, sixth month. In the sixth month, what you give as the third dose is a miracle dose in the child that gives lifetime immunity. The third dose gives the lifetime immunity, not the first and second. So you go by that logic of world science.

He added that the booster shot might be required but the impact of the coronavirus has weakened.

"My feeling is, the virus load has come down in the country. So we'll wait and watch. And enough supplies are also there so not a problem", he said.

However, when asked if a roll-out of the booster shot should be expected any time soon, he refrained from commenting, saying that it's for the policymakers to decide. Currently, Bharat Biotech is seeking approval from the Drug Controller General of India (DCGI) to produce vaccines for children between 2-18 years of age.

Dr Ella has maintained that vaccination in children is necessary, where he had earlier said that children might be passive carriers of the virus as they are likely to not show any symptoms even if they are infected.

Data evaluation and processing will take time

Earlier this month, the DCGI had stated that the data evaluation and processing before giving a nod for Covaxin's emergency use in children will take some more time. 

"It's a sensitive matter. Data evaluation is underway. More data has been submitted," said the body, as per ANI, that is examining the efficacy and safety of the vaccine for children. Republic Media Network earlier reported that Bharat Biotech had submitted data from COVAXIN (BBV152) clinical trials in children aged 2 to 18 years, to the Central Drugs Standard Control Organization (CDSCO).

As per Bharat Biotech, favourable recommendations have been made for Covaxin by the CDSCO and Subject Experts Committee (SEC). 

Image: AP/ANI

Advertisement

Published November 26th, 2021 at 19:51 IST

Your Voice. Now Direct.

Send us your views, we’ll publish them. This section is moderated.

Advertisement
Advertisement

Trending Quicks

A case has been registered against former minister and BRS working president KTR in Hanmakonda
7 minutes ago
Ramban Accident
19 minutes ago
Bitcoin
21 minutes ago
Lok Sabha Elections 2024 LIVE
23 minutes ago
Faridabad Fire: Massive Blaze Engulfs Factory in Bhankri Village, Panic Grips Locality
33 minutes ago
Riyan Parag
34 minutes ago
Raw Mango
36 minutes ago
Byju's leadership dispute
38 minutes ago
Advertisement
Advertisement
Advertisement
Whatsapp logo